According to GlobalData’s medical device pipeline database, 166 Transmucosal Drug Delivery devices are in various stages of development globally. GlobalData’s report Transmucosal drug delivery provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 109 are in active development, while the remaining 67 are in an inactive stage of development. There are 46 products in the early stages of development, and the remaining 63 are in the late stages of development.
Drug delivery devices are used for administration of drug compounds in effective ways. Transmucosal drug delivery is a method of delivering medication through a mucous membrane, such as the lining of the mouth, nose, or throat. This type of drug delivery can be used to deliver a wide range of medications, including pain relievers, hormones, and vaccines. It can be a more effective way to deliver medication than oral administration. This is because the mucous membrane is a very thin layer of tissue that is highly vascularized, meaning that it has a lot of blood vessels. This allows the medication to be absorbed into the bloodstream quickly and efficiently.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Transmucosal Drug Delivery pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Transmucosal Drug Delivery devices. Overall, most of these Transmucosal Drug Delivery pipeline devices are being developed by private entities.
Key players involved in the active development of Transmucosal Drug Delivery include Auritec Pharmaceuticals, Evestra, Karessa Pharma, Dare Bioscience, Conrad, Bespak Europe, Insys Therapeutics, Phoenix Life Sciences International, Mucommune and Auris Medical.
For a complete picture of the developmental pipeline for Transmucosal Drug Delivery devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
